Pluto Bioinformatics

GSE100860: Monitoring Nivolumab binding as a method to clarify the residual therapeutic effects and to characterize the immune profile in antibody bound T cells in previously treated non-small cell lung cancer patients

Bulk RNA sequencing

The goal of this study is to evaluate immune profile in anti PD-1 antibody, Nivolumab, bound CD8 T cells vs Nivolumab unbound CD8 T cells. SOURCE: Daisuke Okuzaki (dokuzaki@biken.osaka-u.ac.jp) - Research institute for microbial diseases, Osaka university